163
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia

ORCID Icon, , , &
Pages 2812-2814 | Received 04 Feb 2021, Accepted 07 May 2021, Published online: 25 May 2021
 

Acknowledgements

The authors recognize the technical assistance of Hong Zhou and Barbara Debrah for organizing medical records.

Author contributions

S.C., H.G., and R.J.K. provided patient care. I.P. and R.J.K. performed ancillary tests, I.R.Y., S.C., H.G., and R.J.K. collected and analyzed results, wrote and reviewed the paper.

Disclosure statement

RJK and IP are coinventors on the NIH patent for Moxetumomab Pasudotox. IY, SC, and HG declare no competing financial interests.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.